Skip to Main Content

Paper Details

A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma.
Eur Urol
42
2021
Advanced Non-Clear Cell Renal Cell Carcinoma, Everolimus, Lenvatinib, Non-clear cell renal cell carcinoma, PARTICIPANTS, PATIENT, Patients, RCC, Solid Tumors, advanced RCC, advanced nccRCC, chromophobe, decreased appetite, diarrhea, everolimus, fatigue, lenvatinib, mTOR, nausea, nccRCC, papillary, patients, tumor, tyrosine, tyrosine kinase, vomiting
Author NameAffiliation
Timothy M KuzelRush University Medical Center
Neeraj AgarwalHuntsman Cancer Center, University of Utah
Ana M Molina
James J HsiehWashington University School of Medicine
James J HsiehWashington University School of Medicine
  • 1 - 5

Datasets

Release 1.2